HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

‘High Dollar’ Conflicts Should Nullify FDA Advisory Panelists – Public Citizen

This article was originally published in The Tan Sheet

Executive Summary

FDA advisory committee members with large financial conflicts of interest should be recused from meetings in which these conflicts may come into play, Public Citizen recommends after conducting a study on voting patterns

You may also be interested in...



FDA Extends Conflict Disclosure Policy To All Advisory Panel Members

FDA's draft guidance on the procedure for disclosing conflicts of interest will extend the agency's disclosure policy to cover all advisory committee members

Draft Conflict Of Interest Policy Affects Status Of Many FDA Cmte. Members

A "significant fraction" of current FDA advisory committee members' eligibility to vote and participate in meetings would be affected by a revised conflict of interest policy, FDA said

FDA advisory committee conflict of interest

"Special government employees" granted conflict of interest waiver for product-specific advisory committee meetings must provide declaration prior to meeting disclosing nature, magnitude of the conflict, agency says in draft guidance released in January. Document provides guidelines on type, amount of information that must be disclosed to the public...

Related Content

Topics

UsernamePublicRestriction

Register

RS125946

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel